BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 19001145)

  • 1. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
    Wolchok JD; Saenger Y
    Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA-4: negative regulator of the immune response and a target for cancer therapy.
    Keilholz U
    J Immunother; 2008 Jun; 31(5):431-9. PubMed ID: 18463542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T-lymphocyte-associated antigen-4.
    Hodi FS
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5238-42. PubMed ID: 17875750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
    Reuben JM; Lee BN; Li C; Gomez-Navarro J; Bozon VA; Parker CA; Hernandez IM; Gutierrez C; Lopez-Berestein G; Camacho LH
    Cancer; 2006 Jun; 106(11):2437-44. PubMed ID: 16615096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
    Agarwala SS
    Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
    Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of anti-CTLA-4 therapies in the treatment of cancer.
    Abrams SI
    Curr Opin Mol Ther; 2004 Feb; 6(1):71-7. PubMed ID: 15011783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T-lymphocyte-associated antigen-4.
    Salama AK; Hodi FS
    Clin Cancer Res; 2011 Jul; 17(14):4622-8. PubMed ID: 21467163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of T cell proliferation by cholera toxin involves the modulation of costimulatory molecules CTLA-4 and CD28.
    Vendetti S; Riccomi A; Sacchi A; Sciaraffia E; Gatta L; Pioli C; De Magistris MT
    Immunol Lett; 2008 Jan; 115(1):59-69. PubMed ID: 18031829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of CTLA-4 in T-cell anergy induced by staphylococcal enterotoxin A in vitro.
    Xu GL; Zhu XH; Guo B; Wu YZ
    Mol Immunol; 2004 May; 41(1):1-8. PubMed ID: 15140570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming immunological tolerance to melanoma: Targeting CTLA-4.
    Hodi FS
    Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S16-23. PubMed ID: 20482528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
    Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
    J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLTA-4 blockade in vivo promotes the generation of short-lived effector CD8 T cells and a more persistent central memory CD4 T cell response.
    Hokey DA; Yan J; Hirao LA; Dai A; Boyer JD; Jure-Kunkel MN; Weiner DB
    J Med Primatol; 2008 Dec; 37 Suppl 2():62-8. PubMed ID: 19187432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors.
    Agarwala SS; Ribas A
    J Immunother; 2010; 33(6):557-69. PubMed ID: 20551840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune modulation in melanoma and advanced cancer therapy: anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibodies.
    Esper P
    Clin J Oncol Nurs; 2009 Oct; 13(5):547-54. PubMed ID: 19793711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.